Do analysts prefer ELYM or ANIX?

Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 167.30%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is ELYM or ANIX more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Anixa Biosciences N/A -71.12% -62.88%

Is ANIX or EPRX more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Eupraxia Pharmaceuticals N/A -63.97% -43.32%

Is ANIX or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Benitec Biopharma N/A -34.82% -34.11%

Is ANIX or PRLD more profitable?

Anixa Biosciences' return on equity of -71.12% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Prelude Therapeutics N/A -75.35% -44.39%

Anixa Biosciences (ANIX) Competitors

$3.18 -0.02 (-0.63%)

As of 04:00 PM Eastern

Compare

ANIX vs. EDIT, ELYM, EPRX, BNTC, and PRLD

Should you buy Anixa Biosciences stock or one of its competitors? Anixa Biosciences's main competitors and comparable companies include Editas Medicine (EDIT), Eliem Therapeutics (ELYM), Eupraxia Pharmaceuticals (EPRX), Benitec Biopharma (BNTC), and Prelude Therapeutics (PRLD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anixa Biosciences compare to Editas Medicine?

Anixa Biosciences (NASDAQ:ANIX) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Anixa Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Anixa Biosciences' return on equity of -71.12% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Editas Medicine	-157.32%	-196.63%	-38.17%

Anixa Biosciences has higher earnings, but lower revenue than Editas Medicine. Anixa Biosciences is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A
Editas Medicine	$40.52M	10.69	-$160.06M	-$0.75	N/A

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 167.30%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 91.49%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Anixa Biosciences is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Editas Medicine had 13 more articles in the media than Anixa Biosciences. MarketBeat recorded 14 mentions for Editas Medicine and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Editas Medicine's score of 0.88 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Very Positive
Editas Medicine	Positive

Summary

Anixa Biosciences beats Editas Medicine on 10 of the 17 factors compared between the two stocks.

How does Anixa Biosciences compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 167.30%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Anixa Biosciences has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A

In the previous week, Anixa Biosciences had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Anixa Biosciences and 0 mentions for Eliem Therapeutics. Anixa Biosciences' average media sentiment score of 1.89 beat Eliem Therapeutics' score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Anixa Biosciences	Very Positive

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Eliem Therapeutics' return on equity of -47.03% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Anixa Biosciences	N/A	-71.12%	-62.88%

Summary

Anixa Biosciences beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Eupraxia Pharmaceuticals?

Anixa Biosciences (NASDAQ:ANIX) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

29.1% of Anixa Biosciences shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anixa Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 167.30%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 167.86%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Anixa Biosciences has higher revenue and earnings than Eupraxia Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

In the previous week, Eupraxia Pharmaceuticals had 10 more articles in the media than Anixa Biosciences. MarketBeat recorded 11 mentions for Eupraxia Pharmaceuticals and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Eupraxia Pharmaceuticals' score of 0.92 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Very Positive
Eupraxia Pharmaceuticals	Positive

Anixa Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Anixa Biosciences on 9 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Benitec Biopharma?

Anixa Biosciences (NASDAQ:ANIX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Benitec Biopharma had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 3 mentions for Benitec Biopharma and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Benitec Biopharma's score of 1.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Very Positive
Benitec Biopharma	Positive

Anixa Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Benitec Biopharma's return on equity of -34.82% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Benitec Biopharma	N/A	-34.82%	-34.11%

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 167.30%. Benitec Biopharma has a consensus target price of $24.80, indicating a potential upside of 97.45%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Anixa Biosciences is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Anixa Biosciences beats Benitec Biopharma on 10 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Prelude Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anixa Biosciences currently has a consensus price target of $8.50, suggesting a potential upside of 167.30%. Prelude Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 38.14%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anixa Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Anixa Biosciences' return on equity of -71.12% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Prelude Therapeutics	N/A	-75.35%	-44.39%

In the previous week, Prelude Therapeutics had 4 more articles in the media than Anixa Biosciences. MarketBeat recorded 5 mentions for Prelude Therapeutics and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Prelude Therapeutics' score of 1.39 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Very Positive
Prelude Therapeutics	Positive

Anixa Biosciences has higher earnings, but lower revenue than Prelude Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	515.16	-$10.93M	-$0.31	N/A
Prelude Therapeutics	$12.14M	36.41	-$99.50M	-$1.00	N/A

Summary

Anixa Biosciences beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$108.87M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-10.26	10.67	269.06	25.28
Price / Sales	515.16	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	7.57	16.78	12.91	6.24
Net Income	-$10.93M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-7.02%	1.74%	1.12%	1.07%
1 Month Performance	-0.31%	1.60%	1.79%	1.03%
1 Year Performance	7.07%	56.43%	67.69%	20.77%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	4.4488 of 5 stars	$3.18 -0.6%	$8.50 +167.3%	+4.9%	$108.87M	$210K	N/A	5	Positive News Gap Down
EDIT Editas Medicine	2.3804 of 5 stars	$2.80 -0.5%	$5.40 +93.2%	-8.8%	$429.26M	$40.52M	N/A	230	Analyst Upgrade
ELYM Eliem Therapeutics	N/A	$14.39 +3.9%	N/A	+793.8%	$428.13M	N/A	N/A	9	High Trading Volume
EPRX Eupraxia Pharmaceuticals	2.4232 of 5 stars	$6.58 -1.3%	$18.00 +173.6%	+22.4%	$426.86M	N/A	N/A	29	News Coverage Earnings Report
BNTC Benitec Biopharma	2.2459 of 5 stars	$12.42 -1.2%	$24.80 +99.8%	+0.4%	$426.46M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. EDIT, ELYM, EPRX, BNTC, and PRLD

How does Anixa Biosciences compare to Editas Medicine?

Summary

How does Anixa Biosciences compare to Eliem Therapeutics?

Summary

How does Anixa Biosciences compare to Eupraxia Pharmaceuticals?

Summary

How does Anixa Biosciences compare to Benitec Biopharma?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. EDIT, ELYM, EPRX, BNTC, and PRLD

How does Anixa Biosciences compare to Editas Medicine?

Do institutionals and insiders believe in ANIX or EDIT?

Which has more volatility and risk, ANIX or EDIT?

Is ANIX or EDIT more profitable?

Which has preferable earnings and valuation, ANIX or EDIT?

Do analysts rate ANIX or EDIT?

Does the media refer more to ANIX or EDIT?

Summary

How does Anixa Biosciences compare to Eliem Therapeutics?

Do analysts prefer ELYM or ANIX?

Which has stronger earnings & valuation, ELYM or ANIX?

Does the media refer more to ELYM or ANIX?

Do institutionals & insiders hold more shares of ELYM or ANIX?

Which has more volatility and risk, ELYM or ANIX?

Is ELYM or ANIX more profitable?

Summary

How does Anixa Biosciences compare to Eupraxia Pharmaceuticals?

Do institutionals and insiders have more ownership in ANIX or EPRX?

Do analysts prefer ANIX or EPRX?

Is ANIX or EPRX more profitable?

Which has better earnings & valuation, ANIX or EPRX?

Does the media refer more to ANIX or EPRX?

Which has more volatility & risk, ANIX or EPRX?

Summary

How does Anixa Biosciences compare to Benitec Biopharma?

Does the media prefer ANIX or BNTC?

Which has more risk & volatility, ANIX or BNTC?

Which has preferable earnings & valuation, ANIX or BNTC?

Do institutionals & insiders have more ownership in ANIX or BNTC?

Is ANIX or BNTC more profitable?

Do analysts recommend ANIX or BNTC?

Summary

How does Anixa Biosciences compare to Prelude Therapeutics?

Do insiders & institutionals hold more shares of ANIX or PRLD?

Do analysts recommend ANIX or PRLD?

Which has more volatility & risk, ANIX or PRLD?

Is ANIX or PRLD more profitable?

Does the media refer more to ANIX or PRLD?

Which has higher valuation & earnings, ANIX or PRLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools